Research And DevelopmentThe GLEAM and VIVID trials are on track for data in 2025, indicating progress in Sana's research and development efforts.
Scientific ValidationThe sustained safety and efficacy profile of UP421 is highly encouraging as it continues to provide in-human results that validate Sana's HIP-technology.
Technological AdvantageSana's HIP-modified islet cell therapy is differentiated from peers as it does not require the use of immunosuppression, unlike other islet cell therapies in development.